Patients with type 2 diabetes mellitus (T2DM) are at high risk for development of atherosclerosis and cardiovascular events. Serum S100A12 levels have been reported to be associated with coronary artery disease (CAD) and T2DM. We sought to assess whether serum S100A12 levels are correlated with the presence and severity of CAD.
Methods
Type 2 diabetes mellitus levels in 188 consecutive patients with T2DM undergoing coronary angiography for the evaluation of CAD. The severity of CAD was assessed by the Coronary Atherosclerosis Index (CAI) scores.
Results
Serum S100A12 levels were significantly higher in patients with T2DM with CAD than in those without CAD. Multivariate logistic regression analysis revealed that serum S100A12 levels were independently associated with the presence of CAD. Serum S100A12 levels were positively correlated with the Coronary Atherosclerosis Index scores after adjusting for other clinical characteristics.
Conclusion
High S100A12 levels are associated with the presence and severity of CAD in patients with T2DM.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
2.
VersariD, DaghiniE, VirdisA, . Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32 (suppl 2): S314–S321.
3.
PietzschJ, HoppmannS. Human S100A12: a novel key player in inflammation?Amino Acids. 2009; 36: 381–389.
4.
LeachST, YangZ, MessinaI, . Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42: 1321–1331.
5.
FoellD, KaneD, BresnihanB, . Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003; 42: 1383–1389.
6.
KomatsudaA, OhtaniH, WakuiH, . Increased serum levels of S100A12 in patients with MPO-ANCA–associated glomerulonephritis. Clin Nephrol. 2006; 66: 315–321.
7.
KosakiA, HasegawaT, KimuraT, . Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 5423–5428.
8.
GoyetteJ, YanWX, YamenE, . Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol. 2009; 183: 593–603.
9.
AlbertiKG, ZimmetPZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998; 15: 539–553.
10.
TatamiR, MabuchiH, UedaK, . Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981; 64: 1174–1184.
11.
HaffnerSM, LehtoS, RönnemaaT, . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.
12.
Calles-EscadonJ, CipollaM. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001; 22: 36–52.
13.
BastaG, SironiAM, LazzeriniG, . Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006; 91: 4628–4634.
14.
YaoD, BrownleeM. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010; 59: 249–255.
15.
AbbasA, AukrustP, DahlTB, . High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke. 2012; 43: 1347–1353.
16.
MoriY, KosakiA, KishimotoN, . Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009; 29: 18–24.
17.
MahajanN, MalikN, BahlA, . Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009; 207: 597–602.
AlexiouP, ChatzopoulouM, PegklidouK, . RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem. 2010; 17: 2232–2252.
20.
BrownleeM, CeramiA, VlassaraH. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1988; 4: 437–451.
21.
BurkeAP, KolodgieFD, ZieskeA, . Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004; 24: 1266–1271.
22.
SaitoT, HojoY, OgoyamaY, . S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J. 2012; 76: 2647–2652.
23.
MorrowDA, WangY, CroceK, . Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008; 155: 49–55.
